2nd Next Generation RNA Therapeutics Summit
Bringing Next Generation RNA Therapies to Patients Faster
Newsletters and Deep Dive digital magazine
Bringing Next Generation RNA Therapies to Patients Faster
The recent acquisition of ImmunoGen by AbbVie, which followed the earlier acquisition of Seagen by Pfizer, has brought renewed attention to antibody-drug conjugates (ADCs), highlighting the
Explore “Innovation as Strategy” framework, providing a guide for employing innovative strategies in life sciences.
Over the last five years, a confluence of trends have combined to reshape the reality of clinical research. COVID-19 pushed decentralised trials into the mainstream.
It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.
We are living in an era of unprecedented advances in cancer treatments with transformative therapies being regularly approved.
The Home of Accelerating Microbial-Based Drug Development
The PM Society is a not-for-profit organisation with 40 years of Giving Back.
Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox